Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T.

Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.

PMID:
30996350
2.

Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.

Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, Grandgenett PM, Kaur S, Batra SK.

EBioMedicine. 2019 Apr;42:375-385. doi: 10.1016/j.ebiom.2019.03.056. Epub 2019 Apr 5.

3.

Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle.

Wang G, Biswas AK, Ma W, Kandpal M, Coker C, Grandgenett PM, Hollingsworth MA, Jain R, Tanji K, Lόpez-Pintado S, Borczuk A, Hebert D, Jenkitkasemwong S, Hojyo S, Davuluri RV, Knutson MD, Fukada T, Acharyya S.

Nat Med. 2018 Jun;24(6):770-781. doi: 10.1038/s41591-018-0054-2. Epub 2018 Jun 6.

4.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

PMID:
29853643
5.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008. No abstract available.

6.

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR.

Cell. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27.

7.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004. Erratum in: Cancer Cell. 2017 Sep 11;32(3):392.

8.

Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis.

Hanson RL, Brown RB, Steele MM, Grandgenett PM, Grunkemeyer JA, Hollingsworth MA.

Oncotarget. 2016 Jun 28;7(26):39996-40011. doi: 10.18632/oncotarget.9557.

9.

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbæk MØ, Lee S, Ørum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander T, Sorensen PH, Daugaard M, Salanti A.

Mol Cancer Res. 2016 Dec;14(12):1288-1299. Epub 2016 Sep 21.

10.

Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis.

Sousa AM, Grandgenett PM, David L, Almeida R, Hollingsworth MA, Santos-Silva F.

APMIS. 2016 Nov;124(11):913-924. doi: 10.1111/apm.12587. Epub 2016 Aug 19. Review.

PMID:
27538373
11.

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.

Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T.

Nature. 2016 Jun 16;534(7607):407-411. doi: 10.1038/nature17988. Epub 2016 Jun 6.

12.

Tumour exosome integrins determine organotropic metastasis.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D.

Nature. 2015 Nov 19;527(7578):329-35. doi: 10.1038/nature15756. Epub 2015 Oct 28.

13.

Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D.

Nat Cell Biol. 2015 Jun;17(6):816-26. doi: 10.1038/ncb3169. Epub 2015 May 18.

14.

MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.

Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM, Batra SK, Hollingsworth MA.

PLoS One. 2013 Oct 25;8(10):e73356. doi: 10.1371/journal.pone.0073356. eCollection 2013.

15.

Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis.

Radhakrishnan P, Grandgenett PM, Mohr AM, Bunt SK, Yu F, Chowdhury S, Hollingsworth MA.

Int J Cancer. 2013 Dec 15;133(12):2824-33. doi: 10.1002/ijc.28322. Epub 2013 Aug 5.

16.

Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.

Radhakrishnan P, Bryant VC, Blowers EC, Rajule RN, Gautam N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MA, Natarajan A.

Clin Cancer Res. 2013 Apr 15;19(8):2025-35. doi: 10.1158/1078-0432.CCR-12-2909. Epub 2013 Feb 26.

17.

Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.

Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA.

Cancer Immunol Immunother. 2013 Feb;62(2):225-36. doi: 10.1007/s00262-012-1324-3. Epub 2012 Aug 5.

18.

Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.

Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA.

Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.

19.

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF.

Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, Hollingsworth MA.

Oncogene. 2010 Oct 21;29(42):5667-77. doi: 10.1038/onc.2010.327. Epub 2010 Aug 9.

20.

A function for a specific zinc metalloprotease of African trypanosomes.

Grandgenett PM, Otsu K, Wilson HR, Wilson ME, Donelson JE.

PLoS Pathog. 2007 Oct 19;3(10):1432-45.

21.

ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.

Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, Johnson KR.

Int J Cancer. 2008 Jan 1;122(1):71-7.

22.

Expression and function of the Trypanosoma brucei major surface protease (GP63) genes.

LaCount DJ, Gruszynski AE, Grandgenett PM, Bangs JD, Donelson JE.

J Biol Chem. 2003 Jul 4;278(27):24658-64. Epub 2003 Apr 21.

23.

Differential expression of GP63 genes in Trypanosoma cruzi.

Grandgenett PM, Coughlin BC, Kirchhoff LV, Donelson JE.

Mol Biochem Parasitol. 2000 Oct;110(2):409-15. No abstract available.

PMID:
11071294

Supplemental Content

Loading ...
Support Center